Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure

Schrier, 2000, The patient with hyponatremia or hypernatremia, Manual of nephrology, 5th ed, 21

Janicic, 2003, Evaluation and management of hypo-osmolality in hospitalized patients, Endocrinol Metab Clin North Am., 32, 459, 10.1016/S0889-8529(03)00004-5

Boscoe, 2006, Cost of illness of hyponatremia in the United States, Cost Eff Resour Alloc., 4, 1, 10.1186/1478-7547-4-10

Upadhyay, 2006, Incidence and prevalence of hyponatremia, Am J Med., 119, S30, 10.1016/j.amjmed.2006.05.005

Zilberberg, 2008, Epidemiology, clinical, and economic outcomes of admission hyponatremia among hospitalized patients, Curr Med Res Opin., 24, 1601, 10.1185/03007990802081675

Klein, 2005, Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study, Circulation., 111, 2454, 10.1161/01.CIR.0000165065.82609.3D

Gheorghiade, 2004, Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial, JAMA., 291, 1963, 10.1001/jama.291.16.1963

Gheorghiade, 2007, Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry, Eur Heart J., 28, 980, 10.1093/eurheartj/ehl542

Gheorghiade, 2007, Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial, Arch Intern Med., 167, 1998, 10.1001/archinte.167.18.1998

Lee, 1986, Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure, Circulation., 73, 257, 10.1161/01.CIR.73.2.257

Lee, 2003, Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model, JAMA., 290, 2581, 10.1001/jama.290.19.2581

Verbalis, 2007, Hyponatremia treatment guidelines 2007: expert panel recommendations, Am J Med., 120, S1, 10.1016/j.amjmed.2007.09.001

Goldsmith, 2005, Vasopressin antagonism in heart failure, J Am Coll Cardiol., 46, 1785, 10.1016/j.jacc.2005.02.095

Konstam, 2007, Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial, JAMA., 297, 1319, 10.1001/jama.297.12.1319

Gheorghiade, 2007, Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials, JAMA., 297, 1332, 10.1001/jama.297.12.1332

Hauptman, 2008, Resource utilization in patients hospitalized with heart failure: insights from a contemporary national hospital database, Am Heart J., 155, 978, 10.1016/j.ahj.2008.01.015

Gheorghiade, 2005, Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST), J Card Fail., 11, 260, 10.1016/j.cardfail.2005.03.009

Blair, 2008, Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure: results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program, J Am Coll Cardiol., 52, 1640, 10.1016/j.jacc.2008.07.056

Hosmer, 2000, Applied logistic regression, 2nd ed, 10.1002/0471722146

Wong, 2002, Systemic diseases associated with disorders of water homeostasis, Endocrinol Metab Clin North Am., 31, 121, 10.1016/S0889-8529(01)00007-X

Shea, 2008, Medical costs of abnormal serum sodium levels, J Am Soc Nephrol., 19, 764, 10.1681/ASN.2007070752

Lee, 2004, Economic burden of heart failure: a summary of recent literature, Heart Lung., 33, 362, 10.1016/j.hrtlng.2004.06.008

Rossi, 2007, Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial, Acute Card Care., 9, 82, 10.1080/17482940701210179